Other Species / Isoforms
  SLC22A1 (rat)      LTP 

LTP (Low Throughput Papers) : The number of records in which this modification site was determined using methods other than discovery mass spectrometry.

 HTP 

HTP (High Throughput Papers): The number of records in which this modification site was assigned using ONLY proteomic discovery mass spectrometry.

 
N97
MRYEVDWNQSTLDCV
0 1
SLC22A1 (human) RRYEVDWNQSALSCV N96
SLC22A1 (mouse) MKYEVDWnQSTLDCV N97-ng
SLC22A1 (rat) MRYEVDWNQSTLDCV N97
A197
SGVLTAVAPDYTSML
0 1
SLC22A1 (human) SGVLMAFsPNYMSML S196-p
SLC22A1 (mouse) SGVLTAVAPDYTSML A197
SLC22A1 (rat) SGVLTAVAPDYTSML A197
S286-p
YYWFVPEsPRWLLsQ
Upstream
Downstream
1 0
Effects on Modified Protein
  • activity, induced
Putative in vivo kinases:
  • PKCA (human)
Treatment
  • dioctanoylglycerol
SLC22A1 (human) YYWCVPESPRWLLSQ S285
SLC22A1 (mouse) YYWFVPESPRWLLSQ S286
SLC22A1 (rat) YYWFVPEsPRWLLsQ S286-p
S292-p
EsPRWLLsQKRtTRA
Upstream
Downstream
1 0
Effects on Modified Protein
  • activity, induced
Putative in vivo kinases:
  • PKCA (human)
Treatment
  • dioctanoylglycerol
SLC22A1 (human) ESPRWLLSQKRNTEA S291
SLC22A1 (mouse) ESPRWLLSQKRTTQA S292
SLC22A1 (rat) EsPRWLLsQKRtTRA S292-p
T296-p
WLLsQKRtTRAVRIM
Upstream
Downstream
1 0
Effects on Modified Protein
  • activity, induced
Putative in vivo kinases:
  • PKCA (human)
Treatment
  • dioctanoylglycerol
SLC22A1 (human) WLLSQKRNTEAIKIM N295
SLC22A1 (mouse) WLLSQKRTTQAVRIM T296
SLC22A1 (rat) WLLsQKRtTRAVRIM T296-p
K309
IMEQIAQKNGKVPPA
0 1
SLC22A1 (human) IMDHIAQKNGKLPPA K308
SLC22A1 (mouse) IMEQIAQkNRKVPPA K309-ub
SLC22A1 (rat) IMEQIAQKNGKVPPA K309
K319
KVPPADLKMLCLEED
0 2
SLC22A1 (human) KLPPADLKMLSLEED K318
SLC22A1 (mouse) KVPPADLkMMCLEED K319-ub
SLC22A1 (rat) KVPPADLKMLCLEED K319
S328-p
LCLEEDAsEKRSPsF
Upstream
Downstream
1 0
Effects on Modified Protein
  • activity, induced
Putative in vivo kinases:
  • PKCA (human)
Treatment
  • dioctanoylglycerol
SLC22A1 (human) LSLEEDVTEKLSPSF T327
SLC22A1 (mouse) MCLEEDASERRSPsF S328
SLC22A1 (rat) LCLEEDAsEKRSPsF S328-p
S334-p
AsEKRSPsFADLFRT
0 2
SLC22A1 (human) VTEKLSPSFADLFRT S333
SLC22A1 (mouse) ASERRSPsFADLFRT S334-p
SLC22A1 (rat) AsEKRSPsFADLFRT S334-p
Y362
WFSCAVLYQGLIMHV
0 1
SLC22A1 (human) WFTDSVLyQGLILHM Y361-p
SLC22A1 (mouse) WFSCAVLYQGLIMHV Y362
SLC22A1 (rat) WFSCAVLYQGLIMHV Y362
K540
GRRKSKAKENTIYLQ
0 1
SLC22A1 (human) LGRKAKPKENtIYLK K538
SLC22A1 (mouse) GRRKSKAkENtIYLQ K540-ub
SLC22A1 (rat) GRRKSKAKENTIYLQ K540
T543
KSKAKENTIYLQVQt
0 2
SLC22A1 (human) KAKPKENtIYLKVQT T541-p
SLC22A1 (mouse) KSKAkENtIYLQVQT T543-p
SLC22A1 (rat) KSKAKENTIYLQVQt T543
T550-p
TIYLQVQtGKSSST_
Upstream
Downstream
1 0
Effects on Modified Protein
  • activity, induced
Putative in vivo kinases:
  • PKCA (human)
Treatment
  • dioctanoylglycerol
SLC22A1 (human) tIYLKVQTSEPSGT_ T548
SLC22A1 (mouse) tIYLQVQTGksPHT_ T550
SLC22A1 (rat) TIYLQVQtGKSSST_ T550-p
K552
YLQVQtGKSSST___
0 1
SLC22A1 (human) YLKVQTSEPSGT___ E550
SLC22A1 (mouse) YLQVQTGksPHT___ K552-ub
SLC22A1 (rat) YLQVQtGKSSST___ K552
S553
LQVQtGKSSST____
0 1
SLC22A1 (human) LKVQTSEPSGT____ P551
SLC22A1 (mouse) LQVQTGksPHT____ S553-p
SLC22A1 (rat) LQVQtGKSSST____ S553